US Bancorp DE Has $31,000 Stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

US Bancorp DE reduced its stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 88.5% in the fourth quarter, HoldingsChannel.com reports. The firm owned 848 shares of the company’s stock after selling 6,520 shares during the period. US Bancorp DE’s holdings in Amphastar Pharmaceuticals were worth $31,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the stock. Illumine Investment Management LLC purchased a new stake in shares of Amphastar Pharmaceuticals during the fourth quarter valued at approximately $633,000. Parkside Financial Bank & Trust raised its stake in Amphastar Pharmaceuticals by 806.5% in the 4th quarter. Parkside Financial Bank & Trust now owns 979 shares of the company’s stock valued at $36,000 after acquiring an additional 871 shares during the period. D.A. Davidson & CO. purchased a new stake in Amphastar Pharmaceuticals during the fourth quarter valued at about $417,000. Principal Financial Group Inc. boosted its position in Amphastar Pharmaceuticals by 3.0% during the fourth quarter. Principal Financial Group Inc. now owns 207,978 shares of the company’s stock worth $7,722,000 after purchasing an additional 5,961 shares during the period. Finally, Rhumbline Advisers increased its stake in shares of Amphastar Pharmaceuticals by 1.4% in the fourth quarter. Rhumbline Advisers now owns 87,327 shares of the company’s stock worth $3,242,000 after purchasing an additional 1,213 shares in the last quarter. 65.09% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on AMPH shares. Wells Fargo & Company started coverage on shares of Amphastar Pharmaceuticals in a report on Friday, November 22nd. They issued an “equal weight” rating and a $55.00 price objective for the company. Piper Sandler cut Amphastar Pharmaceuticals from an “overweight” rating to a “neutral” rating and reduced their price target for the company from $66.00 to $36.00 in a research report on Tuesday, February 4th.

Amphastar Pharmaceuticals Trading Down 1.2 %

Shares of AMPH stock opened at $27.36 on Wednesday. The company has a market capitalization of $1.30 billion, a PE ratio of 9.12, a price-to-earnings-growth ratio of 2.19 and a beta of 0.77. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.61 and a current ratio of 3.43. The business’s fifty day moving average is $32.42 and its 200 day moving average is $40.89. Amphastar Pharmaceuticals, Inc. has a 52-week low of $25.89 and a 52-week high of $53.96.

Insider Buying and Selling

In related news, CFO William J. Peters sold 4,231 shares of the business’s stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $27.54, for a total value of $116,521.74. Following the completion of the sale, the chief financial officer now owns 97,363 shares in the company, valued at $2,681,377.02. The trade was a 4.16 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 27.10% of the stock is owned by company insiders.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.